New Lung Cancer Drug: Afatinib
Afatinib is a potent, irreversible dual inhibitor of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) tyrosine kinases. And according to medical research, afatinib is suitable for the treatment of lung cancer and breast cancer.
Indication symptoms: first-line treatment of advanced non-small cell lung cancer (NSCLC), HER2-positive advanced breast cancer
Usage: Take at least 1 hour before or 2 hours after a meal
Dosage: 40mg once a day
Side effect : Common adverse reactions include diarrhea, nausea, rash, proteinuria, hypertension, and anorexia asymptomatic QT prolongation.
By the way, If you are an individual user, we recommend that you consult your physician prior to use。
If you have other inquire or question, be free contact us.
